1 / 11

The NEXT Treatment for Snoring and Obstructive Sleep Apnea

The NEXT Treatment for Snoring and Obstructive Sleep Apnea. Tom Hedman, PhD Founder. Snoring: 48% of men, 34% of women & growing (obesity, allergies, aging) Sleep deprivation – snorer; sleep cycle disruption, stress – family Can lead to OSA Obstructive Sleep Apnea:

hallie
Download Presentation

The NEXT Treatment for Snoring and Obstructive Sleep Apnea

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The NEXT Treatment for Snoring and Obstructive Sleep Apnea Tom Hedman, PhD Founder

  2. Snoring: • 48% of men, 34% of women & growing (obesity, allergies, aging) • Sleep deprivation – snorer; sleep cycle disruption, stress – family • Can lead to OSA • Obstructive Sleep Apnea: • Breathing interrupted during sleep by obstruction of the airway • US: 4.2% age 16 & older, ~10 million adults & growing • Over age 65: 28% of men, 24% of women

  3. NEXT • NEXT - Nonsurgical EXogenous Crosslink Therapy • Injectable Collagen Crosslinking • Immediate effect • Permanent covalent bonds • Low cost – high profit margin genipingenipinn genipingeni genipingenipingenipin genipingenipingenipin genipin

  4. Equine Soft Palate Collagen Mapping

  5. Wind Tunnel Video: Experiments with untreated (brown) and treated (dark blue) equine soft palates

  6. 69% Reduction in Maximum Transient Deformation

  7. 51% Reduction in Steady State Vibration Amplitude Virtual Elimination of Low Frequency – High Energy Vibration

  8. Competitive Advantage: • Primary competition: • Existing surgical treatments • Oral appliances that alter geometry of pharynx/ upper airway (incl. CPAP) • Minimally invasive “stiffening” procedures • Competition: inconsistent, limited or temporary effectiveness; invasive (surgery), inconvenient or uncomfortable (oral appliances, CPAP); • Existing and emerging minimally invasive procedures rely on formation of scar tissue – which is inherently disorganized, weak, easily degraded • NEXT – Effective! Preserves matrix integrity, strengthens tissue

  9. Patent Portfolio • 10 US and 7 international patents issued or in condition for allowance • Snoring – Obstructive Sleep Apnea specific patent pending • Additional 20+ US and international patents pending

  10. Management Team

  11. Funding required for 2014-2015: $250k ($1.25M initial valuation) Patent prosecution and annuity costs Gap funding R&D – between NIH SBIR Phase I and Phase II grants Partial support for CEO/President – business plan development, market research Contact Tom Hedman for more information: thedman@restinnovations.com

More Related